Lantern Pharma Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on November 21, 2023, regarding a material definitive agreement entered into on the same date. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol LTRN.
Key Financial Metrics
The filing details a specific share repurchase transaction rather than periodic financial performance metrics such as revenue, profit, or cash flow.
- Shares Repurchased: 145,348 shares of common stock.
- Purchase Price: $3.44 per share.
- Total Transaction Value: $499,997.12.
- Counterparties: Bios Fund I QP, LP and Bios Fund I, LP (collectively the "Bios Entities").
Material Changes and Transaction Details
The Bios Entities, which are part of a related family of investment partnerships under common control, collectively beneficially own approximately 14.7% of the Company's issued and outstanding shares. The Company was advised that the motivation for the sale was to generate working capital for the Bios Entities' operations and ensure adequate liquidity, and did not relate to the Company's activities or operations. The transaction is expected to close prior to November 30, 2023.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or new risk factors beyond the standard representations and warranties customary for such agreements. The filing text does not provide a clear value for the company's current cash balance or liquidity position post-transaction.
Key Facts for Investor Verification
- Verify the closing of the $499,997.12 share repurchase transaction before November 30, 2023.
- Confirm the updated beneficial ownership percentage of the Bios Entities following the sale of 145,348 shares.
- Review the company's cash position to assess the impact of the repurchase on working capital.
- Monitor for any subsequent filings regarding the use of proceeds or further transactions with the Bios Entities.